1. An isolated soluble CCR6 receptor polypeptide containing or consisting of an amino acid sequence selected from the group consisting of: (a) an amino acid sequence that has at least 80% identity with respect to the sequence according to SEQ ID NO .: 1, and (b) an amino acid sequence fragment according to (a)； wherein said isolated CCR6 receptor polypeptide is capable of binding to CCL18 and / or CCL20.2. The isolated soluble CCR6 receptor polypeptide according to claim 1, wherein the amino acid sequence according to (a) contains at least 8 consecutive amino acids of the sequence according to SEQ ID NO .: 1.3. The isolated soluble CCR6 receptor polypeptide according to claim 1, wherein said isolated soluble CCR6 receptor polypeptide does not contain a transmembrane domain. A pharmaceutical composition comprising a compound capable of inhibiting the activity and / or expression of CCL18 or CCL20.5. The pharmaceutical composition of claim 4, wherein the compound capable of inhibiting the activity and / or expression of CCL18 or CCL20 is selected from the group consisting of the isolated soluble CCR6 receptor polypeptide according to any one of claims 1-3, a small molecule capable of binding to CCL18 or CCL20 , an aptamer specific for CCL18 or CCL20, an antibody specific for CCL 18 or CCL20, an antisense molecule suitable for reducing or inhibiting the expression of CCL18 or CCL20, and a siRNA molecule suitable for reducing or inhibiting the expression of CCL 18 or CCL20.6. The pharmaceutical composition of claim 4, wherein the composition comprises an additional active compound suitable for the treatment or prevention of inter1. Изолированный растворимый полипептид рецептора CCR6, содержащий или состоящий из аминокислотной последовательности, выбранной из группы, состоящей из:(a) аминокислотной последовательности, которая имеет, как минимум, 80% идентичность по отношению к последовательности согласно SEQ ID NO.: 1,и(b) фрагмента аминокислотной последовательности в со
